. .

/ & /


,
. 1
102

.

18 56%
HbA1C 1%2 -.
, ATT Collaboration 3,
10
o 18%,
5% .
(
, ,
)
,
.
, ,

.

4 ( ),
, .


.

5 .
(
, , . VII, . Von Willebrand,
, C, ...)
( ...) (
, ,
C, IIb, IIa
)
( 1).


, , ,
, . . .
,


.

,
,
.

(80
160 mg/). ATT Collaboration 3
(p< 0,0001) 20%
.
ADA, AACE, IDF
75 160mg/.
6 ( ).

.

. , ( JPAD)7 ,
(80-100mg/.) ( 4, 5 )
20%
() . H
(HR = 0,80 - [95% C.I 0,58 1, 1]). post hoc
65

(HR = 0,68 - [95% C.I 0,46 0,99]),
, (GFR) 60-90 ml/min
(HR = 0,57 [95% C.I 0,36
0,88]).
, ( POPADAD)8

.


50% , 5 ( ) 50%
.
9,10 ( 2
3-4 )
10 12 %
.
(
De Berardis . .
43%),
).
Antithrombotic
Trialists (ATT) collaborators, 6 (95.000 ,
4.000 ). 12%
(RR = 0,88 CI 0,82 0,94)
11.

 9 (102.621 )
20%
,
. (
) 30%
( ) . ,
() ()
=120 = 73 ( ).


. (ESC) 201212

, .
U. S. Preventive Services Task Force (Guidelines)13
45 -79 55 79
(

, .
). ADA ( ) 2010
80-150mg/. > 50
>60 .6
ADA
3 (
)
( Framingham risc
score ).


201314:
> 50 >60


.
( 2)

ASCEND
ACCEPT- D 15.

clopidogrel ( P2Y12)
CAPRIE-
. ,
, clopidogrel,
P 450 ( CYP 2C19)
,
.
6.
() ,

 stent (Des stent)

bare stent16.


prasugel ( P2Y12,
TRITON) ticagrelor ( P2Y12, PLATO)
clopidogrel.
:



.

(turnover)
24
24 (cox-1) .
,
( , ,
, . . .)
.

, ( )


.

| 6
Ferreiro JL. Diabetes and Vascular Research 2010; 7(4): 251-259

( 1)

-
Position Statement of ADA, AHA and the ACCF

(75-162 mg/)

2 1, (10
> 10%)
> 50
>60 ,
: 1) , 2)
, 3) , 4)
, 5)
(C) (1,2)

1) American Diabetes Association. Diabetes Care 2013; 36 (Suppl 1): S11-S66

2) Nikolucci A. & Standl E. Diabetes Care 2011; 34: S150

( 2)


1. The Emerging Risk Factors Collaboration: Diabetes mellitus, fasting blood
glucose concentration, and risk of vascular disease: a collaborative meta-analysis of
102 prospective studies. The Lancet 2010;375: 2215-2222
2. Juutilainen A., Lehto S, Ronnemaa T, Pyorala K, Laakso M. Similarity of the
impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged
subjects, Diabetes Care 2008;31:714-719
3. Baigent C, Blackwell L, Collins R et al. ; Antithrombotic Trialists (ATT)
Collaboration. Aspirin in the primary and secondary prevention of vascular disease:
collaborative data from randomized trials. Lancet 2009;373:1849-1860
4. Turnbull FM, Abraina C, Anderson RJ, et al.; Control group. Intensive glucose
control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52:22882298
5. . : . 2010: .
2010, . 249 - 265
6. Standards of Medical Care in diabetes 2013, ADA. Diabetes Care 2013;suppl. 1:
s12 s60
7. Ogawa H, Nakayama M., Morimoto T, et al.; Japanese Primary Prevention of
atherosclerosis with aspirin for diabetes (JPAD) Trial Investigators. Low dose
aspirin for primary prevention of atherosclerotic events in patients with type 2
diabetesQ a randomized controlled trial. JAMA 2008;300:2134-2141
8. Belch J, MacCuish A, Cambell I et al. Prevention of progression of arterial disease
and diabetes study group; Diabetes Registry Group; Royal College of Physicians
Edinburgh.
The prevention of progression of arterial disease and arterial
(POPADAD) trial: factorial randomized placebo controlled trial of aspirin and
antioxidants in patients with diabetes and asymptomatic peripheral arterial diseas.
BMJ 2008;337:a1840
9. De Berardis G, Sacco M, Strippoli GF, et al. Aspirin for primary prevention of
cardiovascular events in patients with diabetes: A meta-analysis of randomized
controlled trials. BMJ 2009;339:b4531
10. Zhang C, Sun A., Zhang P et al. Aspirin for primary prevention of cardiovascular
events in patients with diabetes: A meta analysis. Diabetes Res Clin Pract
2010;87:211-218
11. S. Kondapally, S. Wijesuriya, R. Sivakumaran et al: Effect of Aspirin on
Vascular and Nonvascular OutcomesMeta-analysis of Randomized Controlled
Trials. Archives of Internal Medicine 2012;172:209-216.
12. European Guidelines on CVD prevention. EHJ 2012;33:1635-1701
13. Wolff T, Miller T. Ko S. Aspirin for the primary prevention of cardiovascular
events: an update of the evidence for the U. S. Preventive Services Task Force. Ann.
Intern. Med 2009;150:405-410
14. .
2013.
15. Nicolucci A., Standl E. : Antiplatelet therapy for every diabetic person? Diabetes
Care 2011;suppl. 2: s150- s154

16. Jos Luis Ferreiro and Dominick J. Angiolillo: Diabetes and Antiplatelet Therapy
in Acute Coronary Syndrome. Circulation 2011;123:798-812.